SCHEMBL12480214

SCHEMBL12480214

CNC(=O)c1cc(Cl)c(F)c(CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
CFD P00746 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
EPHX2 P34913 2/20 0.37
NR1H4 Q96RI1 2/20 0.37
KDM4A O75164 1/20 0.37
KCNA5 P22460 1/20 0.36
MET P08581 1/20 0.35
NAMPT P43490 1/20 0.35
HDAC1 Q13547 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12479663 0.88 EPHX2 (0.43) IDO1CFDHDAC10HDAC6EPHX2
SCHEMBL12479901 0.86 IDO1 (0.40) IDO1CFDHDAC10HDAC6EPHX2
SCHEMBL12480896 0.84 CFD (0.39) IDO1CFDHDAC10HDAC6SLC6A2
SCHEMBL12480132 0.84 CFD (0.42) IDO1ALDH1A1HPGDCFDEPHX2
SCHEMBL12479987 0.81 IDO1 (0.41) IDO1HDAC10HDAC6KDM4AKCNA5
SCHEMBL12480140 0.80 IDO1 (0.36) IDO1CFDHDAC10HDAC6EPHX2
SCHEMBL12480602 0.79 IDO1 (0.40) IDO1ALDH1A1HPGDHDAC10HDAC6
SCHEMBL12481076 0.79 CFD (0.45) ALDH1A1HPGDCFDPOLB
SCHEMBL12480124 0.78 HPGD (0.47) ALDH1A1HPGDCFD
SCHEMBL12480091 0.78 IDO1 (0.39) IDO1ALDH1A1HPGDHDAC10HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 IDO1 1318/4885ALDH1A1 2495/4885HPGD 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.